Drug Research

Lonza to enhance commercial antibody-drug conjugate supply capacity

Lonza is planning to build a commercial-scale aseptic current good manufacturing practice (cGMP) filling line at its site in Stein, Switzerland. The new filling line will facilitate the aseptic filling of highly-potent antibody drug conjugates (ADCs) and lyophilisation under...

Gritgen Therapeutics Launches Commercial GMP Facility in China

Gritgen Therapeutics Co., a biotechnology company focused on gene therapy products, reported the successful validation and launch of operations at its commercial GMP facility in Suzhou China for the production of Gritgen's phase III clinical and commercial product for...

Cellipont and Diakonos to develop cell therapy for glioblastoma

Cellipont Bioservices has signed an agreement with Diakonos Oncology for the development of DOC1021, a cell therapy to treat glioblastoma multiforme (GBM). The parties will carry out the process development and current good manufacturing practice (cGMP) production of DOC1021 for...

Sygnature Discovery collaborates with Axol Bioscience to utilize human iPSC-derived microglial cells in high-content imaging drug discovery screening workflows

Sygnature Discovery, a world-leading integrated drug discovery provider and non-clinical solutions provider, has announced a scientific collaboration with human induced pluripotent stem cell (iPSC) experts, Axol Bioscience. The collaboration aims to explore the incorporation of human iPSC-derived microglia into high-content...

BioCity, AstraZeneca Partner on Treatment of Advanced HCC

BioCity Biopharma and AstraZeneca signed an agreement to collaborate on a Phase Ib/II clinical study to evaluate the safety and efficacy of BioCity's BC3402, a monoclonal antibody (mAb) targeting the T cell immunoglobulin and mucin domain-containing protein 3, also...

NCCS and tech firm to collaborate on Asian-prevalent cancer research

Agilent Technologies Inc. recently signed a Research Collaboration Agreement (RCA) with the National Cancer Centre Singapore (NCCS) outlining their collaboration to accelerate translational cancer research on the genomic landscape of Asian-prevalent cancers over the next two years. The scope of the...

Bharat Serums and Vaccines invests Rs 200 Cr in new biopharmaceutical manufacturing plant in Genome Valley

Bharat Serums and Vaccines Limited (BSV) hosted the groundbreaking ceremony of its new manufacturing plant at Genome Valley in Hyderabad, Telangana, in the presence of K.T Rama Rao, Minister for Municipal Administration and Urban Development; Industries and Commerce; and...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read